Clinical Trials

PL37 for the treatment of neuropathic pain (PL37-C03-2013)

A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabapentin.

EudraCT Number:                           2013-004876-37

Status : Recruitment closed

PL265 Phase 1 Study  (PL265-C01-2014)

Phase I, randomised, double-blind, placebo-controlled single oral dose escalation study to investigate the safety, tolerability and pharmacokinetics of PL265 in young healthy male volunteers.

EudraCT Number:                           2014-000192-41

Status : Completed

Read next

Discover our publications
Press & media coverage
Contact & find us

Pharmaleads SA
11, rue Watt
75013 Paris

Tel: +33 (0)1 44 06 70 00
Fax: +33 (0)1 44 06 60 99

Get the access map